Press Release Archive
-
INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia, Now Commercially Available
-
Depuy Synthes Companies Announces Five-Year Cooperation Agreement With The AO FoundationAgreement Continues 55-Year History of Clinical Innovation and Professional Education
-
Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple MyelomaMarks a critical step forward for the investigational human monoclonal antibody (mAb)
-
Data at EULAR 2015 Showcase Commitment of Janssen to Advancing Innovative Treatments for Immune and Inflammatory DiseasesNew data highlights efficacy and safety of STELARA® (ustekinumab), SIMPONI® (golimumab), sirukumab and guselkumab
-
Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue SarcomaOral presentation (abstract 10503) featured at the Annual Meeting of the American Society of Clinical Oncology
-
Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma PatientsResults from the Phase 2 MMY2002 trial (Abstract LBA8512) featured in the official press program of the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
-
Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic LeukemiaPhase 3 data (abstract LBA7005) featured in the official press program of the 51st annual meeting of the American Society of Clinical Oncology
-
New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with CancerJanssen Expands EXPLORER Cardiovascular Research Program to Include New, Multi-Trial, Prospective Research Program Aimed at Generating New Evidence in Treating and Preventing Cancer-Associated Blood ...
-
STELARA® Receives CHMP Positive Opinion For Treatment Of Adolescents With Moderate To Severe Psoriasis In EuropeSTELARA Recommended for Approval in Paediatric Patients 12 Years and Older with Moderate to Severe Psoriasis
-
Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s MacroglobulinemiaA rare B-cell lymphoma with no EMA-approved treatment options available